A detailed history of Knoll Capital Management, LLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Knoll Capital Management, LLC holds 5,475,516 shares of ALDX stock, worth $30.8 Million. This represents 12.24% of its overall portfolio holdings.

Number of Shares
5,475,516
Previous 5,475,516 -0.0%
Holding current value
$30.8 Million
Previous $17.9 Million 1.22%
% of portfolio
12.24%
Previous 11.18%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$1.47 - $6.06 $3.59 Million - $14.8 Million
2,443,601 Added 80.6%
5,475,516 $19.2 Million
Q3 2023

Nov 14, 2023

BUY
$6.11 - $8.16 $99,269 - $132,575
16,247 Added 0.54%
3,031,915 $20.3 Million
Q2 2023

Aug 15, 2023

BUY
$7.11 - $11.89 $6.74 Million - $11.3 Million
948,508 Added 45.88%
3,015,668 $25.3 Million
Q1 2023

May 15, 2023

BUY
$5.77 - $9.93 $687,033 - $1.18 Million
119,070 Added 6.11%
2,067,160 $20.5 Million
Q4 2022

Feb 14, 2023

BUY
$5.08 - $7.09 $359,587 - $501,865
70,785 Added 3.77%
1,948,090 $13.6 Million
Q3 2022

Nov 14, 2022

BUY
$3.8 - $7.74 $1.42 Million - $2.9 Million
374,845 Added 24.95%
1,877,305 $10 Million
Q2 2022

Aug 15, 2022

BUY
$2.43 - $4.85 $1.81 Million - $3.6 Million
743,055 Added 97.85%
1,502,460 $6 Million
Q4 2021

Feb 14, 2022

BUY
$3.5 - $9.63 $665,000 - $1.83 Million
190,000 Added 33.37%
759,405 $3.04 Million
Q4 2019

Feb 14, 2020

BUY
$4.73 - $7.98 $178,969 - $301,939
37,837 Added 7.12%
569,405 $3.31 Million
Q3 2019

Nov 14, 2019

BUY
$4.41 - $6.12 $9,604 - $13,329
2,178 Added 0.41%
531,568 $2.8 Million
Q2 2019

Aug 14, 2019

BUY
$6.0 - $9.0 $271,764 - $407,646
45,294 Added 9.36%
529,390 $3.18 Million
Q3 2018

Nov 14, 2018

BUY
$6.8 - $14.35 $2.45 Million - $5.17 Million
360,000 Added 290.1%
484,096 $6.32 Million
Q3 2017

Nov 14, 2017

BUY
$3.9 - $10.8 $483,974 - $1.34 Million
124,096
124,096 $893,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $328M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Knoll Capital Management, LLC Portfolio

Follow Knoll Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Knoll Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Knoll Capital Management, LLC with notifications on news.